help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on March 17, 2004, doi:10.1164/rccm.200308-1174OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow OnlineSupplement
Right arrow All Versions of this Article:
200308-1174OCv1
170/3/234    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Covar, R. A.
Right arrow Articles by Szefler, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Covar, R. A.
Right arrow Articles by Szefler, S. J.
American Journal of Respiratory and Critical Care Medicine Vol 170. pp. 234-241, (2004)
© 2004 American Thoracic Society

Original Article

Progression of Asthma Measured by Lung Function in the Childhood Asthma Management Program

Ronina A. Covar, Joseph D. Spahn, James R. Murphy and Stanley J. Szefler for the Childhood Asthma Management Program Research Group

Ira J. and Jacqueline Neimark Laboratory of Clinical Pharmacology; Department of Pediatrics, Division of Allergy-Clinical Immunology; and Division of Biostatistics, National Jewish Medical and Research Center, Denver, Colorado

Correspondence and requests for reprints should be addressed to Stanley J. Szefler, M.D., National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206. E-mail: szeflers{at}njc.org

From the Childhood Asthma Management Program cohort, which was randomly assigned to receive budesonide, nedocromil, or placebo for 4–6 years, we determined the prevalence of and factors associated with at least 1% per year loss in postbronchodilator FEV1% predicted. Participants who had a significant reduction in postbronchodilator FEV1% predicted (SRP), comprised 25.7% of the cohort (n = 990). Using logistic regression, predictors of SRP at baseline were younger age (p = 0.0005), male sex (p < 0.0001), clinic (p = 0.02), and higher postbronchodilator FEV1% predicted (p = 0.02). Examination of the SRPs indicated that the effect of baseline lung function was such that the higher the lung function, the less steep the reduction in postbronchodilator FEV1% predicted (p < 0.0001). A similar proportion of SRPs was found in each treatment group. Among the SRPs, the rate of reduction in postbronchodilator FEV1% predicted was similar in all treatment groups. At a single site where biomarker assessment was performed, SRPs also had more prominent eosinophilic inflammation during the washout period. The course and mechanisms of lung function reduction or slow lung growth velocity in children with asthma must be defined.

Key Words: asthma progression • markers of inflammation • airway inflammation




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
P. M. O'Byrne, S. Pedersen, C. J. Lamm, W. C. Tan, W. W. Busse, and on behalf of the START Investigators Group
Severe Exacerbations and Decline in Lung Function in Asthma
Am. J. Respir. Crit. Care Med., January 1, 2009; 179(1): 19 - 24.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. H. Lee, T. Haselkorn, L. Borish, L. Rasouliyan, B. E. Chipps, and S. E. Wenzel
Risk Factors Associated With Persistent Airflow Limitation in Severe or Difficult-to-Treat Asthma: Insights From the TENOR Study
Chest, December 1, 2007; 132(6): 1882 - 1889.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Peters-Golden and W. R. Henderson Jr.
Leukotrienes
N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
E. H. Walters, D. W. Reid, D. P. Johns, and C. Ward
Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling
Eur. Respir. J., September 1, 2007; 30(3): 574 - 588.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. L. James and S. Wenzel
Clinical relevance of airway remodelling in airway diseases
Eur. Respir. J., July 1, 2007; 30(1): 134 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. E. Wenzel and R. Covar
Update in asthma 2005.
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 698 - 706.
[Full Text] [PDF]

Home page
 ThoraxHome page
P Ernst
Inhaled corticosteroids moderate lung function decline in adults with asthma
Thorax, February 1, 2006; 61(2): 93 - 94.
[Full Text] [PDF]

Home page
 ChestHome page
L. R. Choo-Kang
Becoming a Complete "Asthmologist"
Chest, November 1, 2005; 128(5): 3093 - 3096.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. Bush, F. Accurso, W. MacNee, S. C. Lazarus, and E. Abraham
Cystic Fibrosis, Pediatrics, Control of Breathing, Pulmonary Physiology and Anatomy, and Surfactant Biology in AJRCCM in 2004
Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 545 - 553.
[Full Text] [PDF]

Home page
 PhysiologyHome page
R. J. Homer and J. A. Elias
Airway Remodeling in Asthma: Therapeutic Implications of Mechanisms
Physiology, February 1, 2005; 20(1): 28 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Pedersen
Progression of Asthma: Small Steps and a Long Way to Go
Am. J. Respir. Crit. Care Med., August 1, 2004; 170(3): 206 - 207.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2004 American Thoracic Society 		  2009/2010 ATS Fellows Career Development Awards